0 XP   0   0   0

Mayne Pharma Group Ltd
Buy, Hold or Sell?

Let's analyse Mayne Pharma Group Ltd together

PenkeI guess you are interested in Mayne Pharma Group Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mayne Pharma Group Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Mayne Pharma Group Ltd

I send you an email if I find something interesting about Mayne Pharma Group Ltd.

Quick analysis of Mayne Pharma Group Ltd (30 sec.)










1. Valuation of Mayne Pharma Group Ltd (5 min.)




Current price per share

A$3.79

2. Growth of Mayne Pharma Group Ltd (5 min.)




Is Mayne Pharma Group Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$367.8m$509.3m-$141.5m-38.5%

How much money is Mayne Pharma Group Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$180.8m-$138m-$42.8m?
Net Profit Margin-64.6%-52.2%--

How much money comes from the company's main activities?

3. Financial Health of Mayne Pharma Group Ltd (5 min.)




4. Comparing to competitors in the Drug Manufacturers-General industry (5 min.)




  Industry Rankings (Drug Manufacturers-General)  


Richest
#51 / 79

Most Revenue
#50 / 79

Most Profit
#78 / 79


Fundamentals of Mayne Pharma Group Ltd

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

1.1. Profitability of Mayne Pharma Group Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mayne Pharma Group Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
  • A Net Profit Margin of -64.6% means that $-0.65 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mayne Pharma Group Ltd:

  • The MRQ is -64.6%. The company is making a huge loss. -2
  • The TTM is -64.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-64.6%TTM-64.6%0.0%
TTM-64.6%YOY-52.2%-12.4%
TTM-64.6%5Y-43.4%-21.2%
5Y-43.4%10Y-17.0%-26.4%
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ-64.6%15.7%-80.3%
TTM-64.6%14.8%-79.4%
YOY-52.2%16.6%-68.8%
5Y-43.4%16.4%-59.8%
10Y-17.0%16.6%-33.6%
1.1.2. Return on Assets

Shows how efficient Mayne Pharma Group Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
  • -21.3% Return on Assets means that Mayne Pharma Group Ltd generated $-0.21 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mayne Pharma Group Ltd:

  • The MRQ is -21.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -21.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.3%TTM-21.3%0.0%
TTM-21.3%YOY-14.3%-7.0%
TTM-21.3%5Y-13.1%-8.2%
5Y-13.1%10Y-5.0%-8.1%
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.3%2.5%-23.8%
TTM-21.3%2.8%-24.1%
YOY-14.3%3.2%-17.5%
5Y-13.1%2.8%-15.9%
10Y-5.0%2.4%-7.4%
1.1.3. Return on Equity

Shows how efficient Mayne Pharma Group Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
  • -48.5% Return on Equity means Mayne Pharma Group Ltd generated $-0.49 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mayne Pharma Group Ltd:

  • The MRQ is -48.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -48.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-48.5%TTM-48.5%0.0%
TTM-48.5%YOY-27.2%-21.3%
TTM-48.5%5Y-24.8%-23.7%
5Y-24.8%10Y-9.3%-15.4%
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ-48.5%5.2%-53.7%
TTM-48.5%6.6%-55.1%
YOY-27.2%7.1%-34.3%
5Y-24.8%6.2%-31.0%
10Y-9.3%6.3%-15.6%

1.2. Operating Efficiency of Mayne Pharma Group Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mayne Pharma Group Ltd is operating .

  • Measures how much profit Mayne Pharma Group Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
  • An Operating Margin of 2.7% means the company generated $0.03  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mayne Pharma Group Ltd:

  • The MRQ is 2.7%. The company is operating less efficient.
  • The TTM is 2.7%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ2.7%TTM2.7%0.0%
TTM2.7%YOY1.8%+0.9%
TTM2.7%5Y-4.0%+6.7%
5Y-4.0%10Y6.1%-10.1%
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7%22.0%-19.3%
TTM2.7%17.2%-14.5%
YOY1.8%22.4%-20.6%
5Y-4.0%20.1%-24.1%
10Y6.1%20.1%-14.0%
1.2.2. Operating Ratio

Measures how efficient Mayne Pharma Group Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-General industry mean).
  • An Operation Ratio of 1.00 means that the operating costs are $1.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.004. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.004. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.004TTM1.0040.000
TTM1.004YOY0.947+0.057
TTM1.0045Y0.969+0.035
5Y0.96910Y0.916+0.052
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0040.965+0.039
TTM1.0040.963+0.041
YOY0.9470.982-0.035
5Y0.9690.956+0.013
10Y0.9160.894+0.022

1.3. Liquidity of Mayne Pharma Group Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mayne Pharma Group Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-General industry mean).
  • A Current Ratio of 0.84 means the company has $0.84 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 0.838. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.838. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.838TTM0.8380.000
TTM0.838YOY1.872-1.034
TTM0.8385Y1.971-1.133
5Y1.97110Y1.834+0.137
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8381.645-0.807
TTM0.8381.574-0.736
YOY1.8721.495+0.377
5Y1.9711.743+0.228
10Y1.8341.589+0.245
1.3.2. Quick Ratio

Measures if Mayne Pharma Group Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
  • A Quick Ratio of 0.60 means the company can pay off $0.60 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 0.598. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.598. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.598TTM0.5980.000
TTM0.598YOY1.264-0.666
TTM0.5985Y1.397-0.800
5Y1.39710Y1.271+0.126
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5980.833-0.235
TTM0.5980.916-0.318
YOY1.2640.983+0.281
5Y1.3970.967+0.430
10Y1.2710.981+0.290

1.4. Solvency of Mayne Pharma Group Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mayne Pharma Group Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mayne Pharma Group Ltd to Drug Manufacturers-General industry mean.
  • A Debt to Asset Ratio of 0.57 means that Mayne Pharma Group Ltd assets are financed with 56.7% credit (debt) and the remaining percentage (100% - 56.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 0.567. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.567. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.567TTM0.5670.000
TTM0.567YOY0.473+0.095
TTM0.5675Y0.435+0.133
5Y0.43510Y0.452-0.017
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5670.514+0.053
TTM0.5670.501+0.066
YOY0.4730.522-0.049
5Y0.4350.532-0.097
10Y0.4520.525-0.073
1.4.2. Debt to Equity Ratio

Measures if Mayne Pharma Group Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
  • A Debt to Equity ratio of 129.4% means that company has $1.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.294. The company is able to pay all its debts with equity. +1
  • The TTM is 1.294. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.294TTM1.2940.000
TTM1.294YOY0.900+0.394
TTM1.2945Y0.810+0.484
5Y0.81010Y1.003-0.192
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2941.059+0.235
TTM1.2941.008+0.286
YOY0.9001.101-0.201
5Y0.8101.166-0.356
10Y1.0031.152-0.149

2. Market Valuation of Mayne Pharma Group Ltd

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Mayne Pharma Group Ltd generates.

  • Above 15 is considered overpriced but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
  • A PE ratio of -0.08 means the investor is paying $-0.08 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mayne Pharma Group Ltd:

  • The EOD is -1.224. Company is losing money. -2
  • The MRQ is -0.081. Company is losing money. -2
  • The TTM is -0.081. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-1.224MRQ-0.081-1.144
MRQ-0.081TTM-0.0810.000
TTM-0.081YOY-2.413+2.332
TTM-0.0815Y-4.207+4.126
5Y-4.20710Y8.595-12.802
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
EOD-1.22443.254-44.478
MRQ-0.08145.468-45.549
TTM-0.08140.569-40.650
YOY-2.41355.995-58.408
5Y-4.20757.857-62.064
10Y8.59544.421-35.826
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Mayne Pharma Group Ltd.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 0.004. Very good. +2
  • The TTM is 0.004. Very good. +2
Trends
Current periodCompared to+/- 
MRQ0.004TTM0.0040.000
TTM0.004YOY12.968-12.964
TTM0.0045Y11.189-11.185
5Y11.18910Y61.731-50.542
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ0.00440.731-40.727
TTM0.00473.479-73.475
YOY12.96888.246-75.278
5Y11.189119.285-108.096
10Y61.731243.890-182.159

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mayne Pharma Group Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-General industry mean).
  • A PB ratio of 0.04 means the investor is paying $0.04 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Mayne Pharma Group Ltd:

  • The EOD is 0.579. Very good. +2
  • The MRQ is 0.038. Very good. +2
  • The TTM is 0.038. Very good. +2
Trends
Current periodCompared to+/- 
EOD0.579MRQ0.038+0.541
MRQ0.038TTM0.0380.000
TTM0.038YOY0.652-0.614
TTM0.0385Y0.605-0.567
5Y0.60510Y1.499-0.894
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
EOD0.5793.674-3.095
MRQ0.0383.827-3.789
TTM0.0383.943-3.905
YOY0.6523.565-2.913
5Y0.6053.986-3.381
10Y1.4995.112-3.613
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Mayne Pharma Group Ltd.

3.1. Funds holding Mayne Pharma Group Ltd


4. Summary

4.1. Key Performance Indicators

The key performance indicators of Mayne Pharma Group Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--6.0586.0580%-0.191+103%1.130+436%0.641+846%
Book Value Growth--0.7220.7220%0.740-2%0.850-15%1.620-55%
Book Value Per Share--6.5496.5490%0.491+1234%1.851+254%1.159+465%
Book Value Per Share Growth--13.33813.3380%0.720+1751%3.361+297%2.441+447%
Current Ratio--0.8380.8380%1.872-55%1.971-57%1.834-54%
Debt To Asset Ratio--0.5670.5670%0.473+20%0.435+30%0.452+26%
Debt To Equity Ratio--1.2941.2940%0.900+44%0.810+60%1.003+29%
Dividend Per Share----0%-0%-0%-0%
Eps---3.095-3.0950%-0.133-96%-0.714-77%-0.343-89%
Eps Growth---21.340-21.3400%-0.186-99%-4.285-80%-0.863-96%
Free Cash Flow Per Share---0.139-0.1390%-0.016-89%-0.045-68%-0.112-20%
Free Cash Flow Per Share Growth---6.724-6.7240%1.482-554%-0.953-86%-6.908+3%
Free Cash Flow To Equity Per Share--0.1850.1850%-0.042+123%0.016+1031%0.046+302%
Free Cash Flow To Equity Per Share Growth--6.4396.4390%0.503+1181%1.606+301%2.109+205%
Gross Profit Margin--1.3821.3820%1.272+9%1.433-4%0.973+42%
Intrinsic Value_10Y_max--12.053--------
Intrinsic Value_10Y_min--0.240--------
Intrinsic Value_1Y_max--0.212--------
Intrinsic Value_1Y_min---0.078--------
Intrinsic Value_3Y_max--1.396--------
Intrinsic Value_3Y_min---0.148--------
Intrinsic Value_5Y_max--3.495--------
Intrinsic Value_5Y_min---0.122--------
Net Profit Margin---0.646-0.6460%-0.522-19%-0.434-33%-0.170-74%
Operating Margin--0.0270.0270%0.018+47%-0.040+250%0.061-56%
Operating Ratio--1.0041.0040%0.947+6%0.969+4%0.916+10%
Pb Ratio0.579+93%0.0380.0380%0.652-94%0.605-94%1.499-97%
Pe Ratio-1.224-1416%-0.081-0.0810%-2.413+2887%-4.207+5108%8.595-101%
Peg Ratio--0.0040.0040%12.968-100%11.189-100%61.731-100%
Price Per Share3.790+93%0.2500.2500%0.320-22%0.467-46%0.744-66%
Price To Total Gains Ratio0.626+93%0.0410.0410%-1.680+4170%-17.147+41648%5.389-99%
Profit Growth--0.6900.6900%-0.212+131%0.103+571%1.709-60%
Quick Ratio--0.5980.5980%1.264-53%1.397-57%1.271-53%
Return On Assets---0.213-0.2130%-0.143-33%-0.131-39%-0.050-76%
Return On Equity---0.485-0.4850%-0.272-44%-0.248-49%-0.093-81%
Revenue Growth--1.0591.0590%0.877+21%0.945+12%1.310-19%
Total Gains Per Share--6.0586.0580%-0.191+103%1.130+436%0.641+846%
Total Gains Per Share Growth--33.79433.7940%-29.984+189%0.945+3476%5.505+514%
Usd Book Value--367810624.000367810624.0000%509396455.800-28%610057017.760-40%456280989.080-19%
Usd Book Value Change Per Share--3.9993.9990%-0.126+103%0.746+436%0.423+846%
Usd Book Value Per Share--4.3234.3230%0.324+1234%1.222+254%0.765+465%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---2.044-2.0440%-0.088-96%-0.471-77%-0.226-89%
Usd Free Cash Flow---7825350.600-7825350.6000%-16569039.400+112%-18330717.080+134%-87931179.740+1024%
Usd Free Cash Flow Per Share---0.092-0.0920%-0.011-89%-0.029-68%-0.074-20%
Usd Free Cash Flow To Equity Per Share--0.1220.1220%-0.028+123%0.011+1031%0.030+302%
Usd Price Per Share2.502+93%0.1650.1650%0.211-22%0.308-46%0.491-66%
Usd Profit---180861790.000-180861790.0000%-138035936.400-24%-131419676.080-27%-55666347.480-69%
Usd Revenue--279868683.000279868683.0000%264291924.200+6%308172909.440-9%233488312.600+20%
Usd Total Gains Per Share--3.9993.9990%-0.126+103%0.746+436%0.423+846%
 EOD+3 -2MRQTTM+0 -0YOY+21 -195Y+19 -2110Y+19 -21

4.2. Fundamental Score

Let's check the fundamental score of Mayne Pharma Group Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.224
Price to Book Ratio (EOD)Between0-10.579
Net Profit Margin (MRQ)Greater than0-0.646
Operating Margin (MRQ)Greater than00.027
Quick Ratio (MRQ)Greater than10.598
Current Ratio (MRQ)Greater than10.838
Debt to Asset Ratio (MRQ)Less than10.567
Debt to Equity Ratio (MRQ)Less than11.294
Return on Equity (MRQ)Greater than0.15-0.485
Return on Assets (MRQ)Greater than0.05-0.213
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Mayne Pharma Group Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.435
Ma 20Greater thanMa 503.728
Ma 50Greater thanMa 1003.864
Ma 100Greater thanMa 2003.647
OpenGreater thanClose3.900
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-06-302019-06-302020-06-302021-06-302022-06-30
Net Working Capital  300,870-40,253260,61711,077271,694-77,693194,001-292,804-98,803
Tax Provision  -41,199-33,644-74,84335,698-39,145-15,660-54,805110,93756,132
Income Tax Expense  -32,530-37,436-69,96629,134-40,832-13,973-54,805110,93756,132



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets1,287,926
Total Liabilities730,806
Total Stockholder Equity564,773
 As reported
Total Liabilities 730,806
Total Stockholder Equity+ 564,773
Total Assets = 1,287,926

Assets

Total Assets1,287,926
Total Current Assets511,618
Long-term Assets511,618
Total Current Assets
Cash And Cash Equivalents 96,672
Net Receivables 268,241
Inventory 108,908
Other Current Assets 37,797
Total Current Assets  (as reported)511,618
Total Current Assets  (calculated)511,618
+/-0
Long-term Assets
Property Plant Equipment 225,855
Goodwill 22,127
Intangible Assets 405,387
Long-term Assets Other 4,450
Long-term Assets  (as reported)776,308
Long-term Assets  (calculated)657,819
+/- 118,489

Liabilities & Shareholders' Equity

Total Current Liabilities610,421
Long-term Liabilities120,385
Total Stockholder Equity564,773
Total Current Liabilities
Short-term Debt 407,993
Short Long Term Debt 405,367
Accounts payable 63,571
Other Current Liabilities 138,857
Total Current Liabilities  (as reported)610,421
Total Current Liabilities  (calculated)1,015,788
+/- 405,367
Long-term Liabilities
Long term Debt Total 5,673
Capital Lease Obligations 8,299
Other Liabilities 114,712
Long-term Liabilities  (as reported)120,385
Long-term Liabilities  (calculated)128,684
+/- 8,299
Total Stockholder Equity
Common Stock1,238,537
Retained Earnings -822,406
Other Stockholders Equity 148,642
Total Stockholder Equity (as reported)564,773
Total Stockholder Equity (calculated)564,773
+/-0
Other
Capital Stock1,238,537
Cash and Short Term Investments 96,672
Common Stock Shares Outstanding 78,575
Liabilities and Stockholders Equity 1,295,579
Net Debt 316,994
Net Invested Capital 970,140
Net Tangible Assets -591,904
Net Working Capital -98,803
Short Long Term Debt Total 413,666



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-30
> Total Assets 
29
15,510
11,693
8,036
71,149
53,677
53,933
233,391
265,820
528,946
1,557,381
1,914,920
1,830,507
1,636,333
1,825,180
1,463,184
1,287,926
1,287,9261,463,1841,825,1801,636,3331,830,5071,914,9201,557,381528,946265,820233,39153,93353,67771,1498,03611,69315,51029
   > Total Current Assets 
0
15,453
11,648
8,013
32,529
18,838
23,255
61,909
65,895
156,820
1,108,650
429,003
480,767
471,946
490,947
416,528
511,618
511,618416,528490,947471,946480,767429,0031,108,650156,82065,89561,90923,25518,83832,5298,01311,64815,4530
       Cash And Cash Equivalents 
29
15,303
11,531
7,936
19,709
5,807
11,596
18,938
14,813
59,201
47,481
63,027
87,312
89,004
137,785
97,980
96,672
96,67297,980137,78589,00487,31263,02747,48159,20114,81318,93811,5965,80719,7097,93611,53115,30329
       Short-term Investments 
0
0
0
0
0
0
0
1,825
1,172
2,229
3,458
6,208
6,747
563
0
0
0
0005636,7476,2083,4582,2291,1721,8250000000
       Net Receivables 
0
80
47
39
5,999
5,697
3,821
24,622
29,805
64,657
123,716
232,716
252,715
256,580
195,908
183,283
268,241
268,241183,283195,908256,580252,715232,716123,71664,65729,80524,6223,8215,6975,9993947800
       Other Current Assets 
0
70
70
37
321
911
594
2,931
2,869
8,289
895,052
20,658
51,837
26,014
63,257
32,755
37,797
37,79732,75563,25726,01451,83720,658895,0528,2892,8692,9315949113213770700
   > Long-term Assets 
0
57
45
23
38,621
34,839
30,678
171,482
199,925
372,126
448,731
1,485,917
1,349,740
1,164,387
1,334,233
1,046,656
776,308
776,3081,046,6561,334,2331,164,3871,349,7401,485,917448,731372,126199,925171,48230,67834,83938,6212345570
       Property Plant Equipment 
0
57
45
23
21,047
21,457
22,224
55,036
53,409
59,597
84,449
189,272
230,051
236,034
238,244
221,595
225,855
225,855221,595238,244236,034230,051189,27284,44959,59753,40955,03622,22421,45721,0472345570
       Goodwill 
0
0
0
0
391
391
391
47,197
47,476
58,436
60,115
58,217
20,616
21,725
22,174
20,346
22,127
22,12720,34622,17421,72520,61658,21760,11558,43647,47647,1973913913910000
       Long Term Investments 
0
0
0
0
0
0
0
0
4,076
0
0
0
0
0
0
0
0
000000004,07600000000
       Intangible Assets 
0
0
0
0
13,835
7,792
3,803
68,273
93,639
244,524
272,368
1,177,224
1,033,910
775,907
940,117
615,808
405,387
405,387615,808940,117775,9071,033,9101,177,224272,368244,52493,63968,2733,8037,79213,8350000
       Other Assets 
0
0
0
0
3,347
5,199
4,260
18,981
34,763
9,569
31,799
152,815
167,389
183,499
174,398
-302,376
-606,224
-606,224-302,376174,398183,499167,389152,81531,7999,56934,76318,9814,2605,1993,3470000
> Total Liabilities 
7
996
255
332
45,600
29,503
23,333
112,502
106,546
206,744
1,181,160
602,496
595,350
622,258
782,867
691,605
730,806
730,806691,605782,867622,258595,350602,4961,181,160206,744106,546112,50223,33329,50345,6003322559967
   > Total Current Liabilities 
7
991
253
318
23,167
14,939
12,304
42,111
30,379
95,078
1,055,924
199,895
179,897
211,329
219,253
222,527
610,421
610,421222,527219,253211,329179,897199,8951,055,92495,07830,37942,11112,30414,93923,1673182539917
       Short-term Debt 
0
3
3
2
7,587
2,339
0
7,471
2,374
2,229
503
13,124
58
50,881
44,836
54,043
407,993
407,99354,04344,83650,8815813,1245032,2292,3747,47102,3397,5872330
       Short Long Term Debt 
0
0
0
0
0
0
0
0
48,030
61,756
76,834
13,011
374,190
50,861
44,836
51,158
405,367
405,36751,15844,83650,861374,19013,01176,83461,75648,03000000000
       Accounts payable 
7
166
135
119
2,227
2,142
2,893
6,832
7,131
51,572
135,508
66,593
63,888
50,443
29,842
42,363
63,571
63,57142,36329,84250,44363,88866,593135,50851,5727,1316,8322,8932,1422,2271191351667
       Other Current Liabilities 
0
821
115
197
13,353
10,458
9,411
27,808
20,874
43,506
919,913
120,178
115,951
110,005
144,575
126,121
138,857
138,857126,121144,575110,005115,951120,178919,91343,50620,87427,8089,41110,45813,3531971158210
   > Long-term Liabilities 
0
6
2
14
22,433
14,564
11,029
70,391
76,167
111,666
125,236
402,601
415,453
410,929
563,614
469,078
120,385
120,385469,078563,614410,929415,453402,601125,236111,66676,16770,39111,02914,56422,43314260
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
62,754
76,331
327,122
374,132
318,501
353,211
292,776
5,673
5,673292,776353,211318,501374,132327,12276,33162,754000000000
       Other Liabilities 
0
6
2
14
15,856
10,086
7,299
10,594
8,726
49,910
48,905
75,479
40,494
92,430
210,403
176,302
114,712
114,712176,302210,40392,43040,49475,47948,90549,9108,72610,5947,29910,08615,85614260
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
33,438
51,562
72,048
91,611
102,225
53,373
40,700
-491,283
-729,163
-729,163-491,28340,70053,373102,22591,61172,04851,56233,43800000000
> Total Stockholder Equity
21
14,514
11,438
7,704
25,550
24,174
30,600
120,889
159,274
310,870
363,749
1,303,838
1,226,464
1,007,766
1,037,547
768,357
564,773
564,773768,3571,037,5471,007,7661,226,4641,303,838363,749310,870159,274120,88930,60024,17425,5507,70411,43814,51421
   Common Stock
30
15,908
15,869
15,869
29,649
31,870
32,016
118,302
137,498
255,834
263,161
1,130,404
1,131,761
1,140,008
1,238,584
1,238,537
1,238,537
1,238,5371,238,5371,238,5841,140,0081,131,7611,130,404263,161255,834137,498118,30232,01631,87029,64915,86915,86915,90830
   Retained Earnings Total Equity00000000000000000
   Accumulated Other Comprehensive Income 
0
439
875
902
1,714
960
1,087
7,461
5,360
30,861
39,058
23,337
71,178
125,099
149,603
88,883
148,642
148,64288,883149,603125,09971,17823,33739,05830,8615,3607,4611,0879601,7149028754390
   Capital Surplus 00000000000000000
   Treasury Stock00000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
5,360
27,631
29,928
23,337
71,178
125,011
149,603
88,883
148,642
148,64288,883149,603125,01171,17823,33729,92827,6315,36000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2022-06-30)

Gross Profit (+$)
totalRevenue423,915
Cost of Revenue-253,769
Gross Profit170,146170,146
 
Operating Income (+$)
Gross Profit170,146
Operating Expense-171,691
Operating Income11,316-1,545
 
Operating Expense (+$)
Research Development14,661
Selling General Administrative28,651
Selling And Marketing Expenses104,600
Operating Expense171,691147,912
 
Net Interest Income (+$)
Interest Income461
Interest Expense-32,098
Other Finance Cost-331
Net Interest Income-31,968
 
Pretax Income (+$)
Operating Income11,316
Net Interest Income-31,968
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-217,818240,450
EBIT - interestExpense = -20,782
-217,818
-241,852
Interest Expense32,098
Earnings Before Interest and Taxes (EBIT)11,316-185,720
Earnings Before Interest and Taxes (EBITDA)92,397
 
After tax Income (+$)
Income Before Tax-217,818
Tax Provision-56,132
Net Income From Continuing Ops-273,950-273,950
Net Income-273,950
Net Income Applicable To Common Shares-263,343
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-492
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses425,460
Total Other Income/Expenses Net-229,13431,968
 

Technicals of Mayne Pharma Group Ltd

1. Trend Indicators

1.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I